Endocan and Atherosclerosis

Angiology

Volumn 66, Issue 5, 2015, Pages 490-

  Balta, Sevket ^a   Mikhailidis, Dimitri P ^b   Demirkol, Sait ^c   Celik, Turgay ^c   Ozturk, Cengiz ^c   Iyisoy, Atila ^c  

^a Eski ehir Military Hospital   (Turkey)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOCAN; UNCLASSIFIED DRUG; VALSARTAN; AUTACOID; PROTEOGLYCAN; TUMOR PROTEIN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BEHCET DISEASE; CARDIOVASCULAR RISK; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; HYPERTENSION; INFLAMMATION; LETTER; PSORIASIS; BLOOD; FEMALE; MALE;

FEMALE; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; MALE; NEOPLASM PROTEINS; PROTEOGLYCANS;

EID: 84928037208     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319715568973     Document Type: Letter

References (9)

1. Aparci M, Isilak Z, Uz O, Yalcin M, Kucuk U. Endocan and Endothelial Dysfunction. Angiology. 2015 ; 66 (5). 488-489
2. Balta S, Mikhailidis DP, Demirkol S, et al. Endocan - a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014 ; 65 (9). 773-777
3. Unlu M, Karaman M, Ay SA, et al. The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients. Clin Exp Hypertens. 2013 ; 35 (6). 418-423
4. Karaman M, Balta S, Ay SA, et al. The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. Clin Exp Hypertens. 2013 ; 35 (7). 516-522
5. Ozturk C, Balta S, Balta I, et al. Neutrophil-lymphocyte ratio and carotid-intima media thickness in patients with behcet disease without cardiovascular involvement. Angiology. 2015 ; 66 (3). 291-296
6. Balta I, Balta S, Koryurek OM, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014 ; 70 (2). 291-296
7. Balta I, Balta S, Demirkol S, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013 ; 169 (5). 1066-1070
8. Celik T, Balta S, Karaman M, et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press. 2015 ; 24 (1). 55-60
9. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis. 2008 ; 200 (1). 1-12